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c h a p t e r
Amiodarone is effective for long-term maintenance of sinus rhythm after electrical
cardioversion of refractory atrial fibrillation or flutter. To examine its efficacy and
safety for pharmacologic conversion of these arrhythmias, we studied 129 patients
with refractory atrial fibrillation or flutter who had failed previous intensive
conventional antiarrhythmic treatment. In anticipation of electrical cardioversion,
patients were loaded with amiodarone, 600 mg/ day during a 4-week period. The
main outcome measure was pharmacologic conversion during this period. During the
loading period, 23 patients (18%) converted to sinus rhythm. When analyzed in a
multivariate model, conversion was related to desethylamiodarone plasma level
(p=0.0006), arrhythmia duration (p=0.04), left atrial area (p=0.02), and concomitant
treatment with verapamil (p=0.01). During ongoing atrial fibrillation after loading,
the ventricular rate decreased from 100 ± 25 to 87 ± 27 beats/ min (p <0.001).
Amiodarone appeared to be safe and did not have to be discontinued because of
intolerable side effects. Thus, amiodarone loading is safe and is still able to convert
refractory atrial fibrillation or flutter. Conversion is related to increased
desethylamiodarone plasma levels and concomitant treatment with verapamil.
Because prolonged loading may increase desethylamiodarone plasma
concentrations, this may enhance efficacy and obviate the need for electrical
cardioversion.
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a b s t r a c t
Concerns have been raised regarding the safety of drugs with class III properties in
patients with atrial fibrillation () with respect to the possibility of bradycardia-
dependent torsade de pointes occurring after conversion to sinus rhythm. Also, it has
never been investigated whether amiodarone is safe in outpatients for the control of
heart rate or bradyarrhythmias during ongoing . The present prospective study
investigates the efficacy and safety of amiodarone for pharmacologic conversion of 
or atrial flutter in  patients with refractory arrhythmia, and it relates patient
characteristics and drug plasma levels to the conversion rate.
Patients One hundred twenty-nine consecutive patients with chronic  or flutter
were considered candidates for preparatory amiodarone treatment in anticipation of
electrical cardioversion. Eighty-nine of these patients participated in a study described
previously. Criteria for prophylactic treatment with amiodarone were also described
previously by Crijns et al. In short, amiodarone was administered only as a 'last resort'
drug in patients who failed to maintain sinus rhythm after previous cardioversions
despite serial antiarrhythmic drug treatment. Furthermore, it was used in patients in
whom other antiarrhythmic drug treatment was contraindicated or in whom it was
not possible to restore sinus rhythm during a previous electrical cardioversion.
Exclusion criteria were () paroxysmal , () myocardial infarction or unstable angina
within  months before entry into the study, () sick sinus syndrome or
atrioventricular conduction disturbances without artificial pacemaker and ()
hyperthyroidism. In all patients, the arrhythmia was symptomatic. All patients had
undergone electrical cardioversion at least once before (median , range -). Ninety-
six patients had failed long-term maintenance of sinus rhythm after cardioversion
despite serial cardioversion treatment and serial administration of an average of . ±
. antiarrhythmic drugs. In the remaining  patients, treatment with other
antiarrhythmic drugs was contraindicated, mainly because of impaired left ventricular
function. In  patients previous electrical cardioversion was not successful. The
clinical characteristics of the patients are presented in table .
The study was approved by the institutional review board, and informed consent for
participation in the study was obtained from all patients.
Amiodarone Loading Reg imen and Study Protocol Before
starting amiodarone, all antiarrhythmic drugs were discontinued for at least  half-
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lives. Atrioventricular nodal blocking drugs, instituted to obtain adequate ventricular
rate control (digoxin, calcium antagonists or -blockers), were allowed during the
loading period. Because of the known interaction of amiodarone with digitalis, the
dose of the latter was reduced by % after initiating amiodarone treatment. Patients
received oral anticoagulation therapy to maintain an international normalized ratio
between . and .. A -lead electrocardiogram, chest x-ray and  h Holter monitor
were performed at baseline. Two-dimensional echocardiography was used to
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Table 1 Characteristics of the 129 study patients.
Age (years) 64 ± 10
Male/female (n) 81/48
AF/Flutter 107/22
Underlying Heart Disease (%)*
Coronary artery disease 39
Rheumatic valve disease 16
Mitral valve disease 26
Aortic valve disease 19
Systemic hypertension 24




Median duration, range (months) 53, 1-348
Number of:
Previous electrical cardioversions 1.9 ± 1.4
Previous antiarrhythmic drugs 2.0 ± 0.7
Concomitant negative chronotropic medication (%)
Digitalis 40
Verapamil 29
Both digitalis and verapamil 20
Betablocker 14
New York Heart Association 
Class I (%) 23
Class II (%) 52
Class III-IV (%) 25
Echocardiographic variables:
Left atrial size, long axis view (mm) 47 ± 7
Left atrial size, apical view (mm) 70 ± 7
Left atrial area (mm2) 2600 ± 530
Right atrial size 61 ± 7
Left ventricular enddiastolic diameter (mm) 54 ± 8
Left ventricular endsystolic diameter (mm) 39 ± 10
Fractional Shortening (%) 29 ± 10
*more than 1 disease entity per patient; n indicates number. 
determine end-systolic and end-diastolic diameters. Left atrial area was calculated
from  left atrial diameters (long axis and apical view) using the following formula:
left atrial area = (. x left atrium long axis) x (. x left atrium apical) x .
Routine clinical laboratory tests, including thyroid function tests, were performed.
Amiodarone was initiated on an outpatient basis at a loading dose of  mg/ day for
 weeks. At the end of this period, patients visited the outpatient department. A -lead
electrocardiogram was repeated to determine cardiac rhythm and to compare heart
rate, , , and c intervals before and after loading. Blood was obtained for the
determination of amiodarone and desethylamiodarone plasma levels using high-
pressure liquid chromatography. Patients who were still in  at that time underwent
direct-current electrical cardioversion.
Definit ion of Ter ms Chronic  or flutter was defined as repeatedly
documented arrhythmia, without intercurrent sinus rhythm on routine -lead
electrocar-diograms recorded at consecutive outpatient visits before inclusion. To
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Figure 1Amiodarone and desethylamiodarone plasma concentrations after 1 month of amiodarone loading in
all 129 patients, comparing patients converting pharmacologically () and those who did not (•).
Patients with an amiodarone concentration < 1.2 mg/l or desethylamiodarone level < 0.9 mg/l were
unlikely to convert (dashed lines).
exclude patients with paroxysmal (stress-induced) adrenergic  during these visits,
we performed  h Holter monitoring. Underlying heart disease was determined from
the patient's history and physical examination, as well as from chest x-ray,
echocardiography, and, if available, from coronary angiography. Total arrhythmia
duration was defined as the duration of arrhythmia history from the first episode of
chronic  or flutter. Proarrhythmia was defined according to the criteria proposed by
Horowitz et al.
Stat ist ical  Analysis The main outcome measure of the study was
conversion to sinus rhythm within  month after the start of the loading period. Data
are reported as the mean value ±  . Median values were used in case of a nonuni-
form distribution of variables. For the comparison of  groups, continuous, normally
distributed variables were tested by one-way analysis of variance. Variables with an
nonuniform distribution were tested with Wilcoxon’s -sample test. Frequencies were
compared by Fisher’s exact test for equality of proportions. To determine variables
related to conversion, logistic regression was performed. Linearity of the continuous
variables in relation to conversion was assessed by evaluating the coefficients of the
quartiles of their distribution. In cases of a linear trend of the estimated coefficients of
the different groups, the variable was introduced as continuous. If no linearity was
apparent, the variable was categorized by taking together the quartiles with similar
coefficients.
A p value <. was considered statistically significant; a p value between . and
. was considered marginally significant.
During an amiodarone loading phase of  ±  days, patients received a mean total
dose of  ±  g. Twenty-three patients (%) converted to sinus rhythm, whereas the
remaining  patients were still in  or flutter after this period. The latter patients
underwent subsequent electrical cardioversion, which was successful in  (%). 
duration increased from  ±  ms to   ±  ms (p<.). - and c-intervals
increased from  ±  to  ±  ms (p<.) and from  ±  to  ±  ms
(p=.), respectively. In the  patients who were still in  or flutter, heart rate at
rest decreased from  ±  to  ±  beats per minute (p <.).
Clinical  Var iables  Assoc iated With Conversion Dur ing
Oral  Amiodarone Therapy  Tables  and  compare the clinical
characteristics of patients who converted pharmacologically while receiving
amiodarone with those who did not. Analyzed in a univariate model, amiodarone and
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desethylamiodarone plasma levels were associated with conversion to sinus rhythm.
Furthermore, in the group of patients who converted during the loading period, there
were significantly more patients treated with verapamil. On the other hand, a long total
arrhythmia duration was an unfavorable factor. When analyzed in a multivariate
model, amiodarone plasma level did not maintain statistical significance. In contrast,
independent predictors of conversion were desethylamiodarone plasma level
(p=.), arrhythmia duration (p=.), left atrial area (p=.) and concomitant
treatment with verapamil (p=.) (table ). There were no significant differences in
the clinical characteristics or drug plasma levels between patients treated with or
without verapamil.
Amiodarone and its  Metabolite Figure  shows amiodarone and
desethylamiodarone plasma concentrations in all patients  month after initiation of
amiodarone therapy. Patients who converted pharmacologically tended to have higher
amiodarone and desethylamiodarone plasma levels than those who failed to convert.
Although there was a considerable overlap in plasma levels between both groups,
conversion was unlikely to occur when the amiodarone level was <. mg/ml, or
desethylamiodarone was <. mg/ml.
Hear t  Rate  at  Rest In the  patients who failed to convert during loading,
the heart rate at rest fell significantly after  month of amiodarone treatment from
Figure 2Reduction in resting heart rate by amiodarone in 43 patients with a stable dose of negative
chronotropic medication during ongoing AF. A, there was a significant correlation between reduction
in heart rate at rest and the plasma amiodarone concentration (Pearson correlation coefficient  = -
0.40, p=0.007). B, no significant relation between plasma desethylamiodarone concentration and
heart rate reduction could be found (Pearson correlation coefficient = - 0.08, p=0.62). Bpm indicates
beats/ minute.
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 ±  to  ±  beats/ min (p <.). Of note, in anticipation of a major reduction
in ventricular rate during ongoing , the administration of beta-blockers or
verapamil was stopped in  of these patients, in addition to the % reduction in the
dose of digitalis. Figure  depicts the correlation between reduction in heart rate at rest
and drug plasma concentrations in the  patients in whom the dose of concomitant
negative chronotropic medication was unchanged. There appeared to be a significant
relation between rate reduction and amiodarone serum concentrations (figure A,
p=.). No relation between heart rate reduction and desethylamiodarone serum
levels was found (figure B, p=.).
Table 2 Clinical characteristics associated with pharmacological conversion during amiodarone loading;
univariate analysis
Conversion No Conversion p
(n=23) (n=106)
Age (years) 66 ± 9 63 ± 10 NS
Male/Female (%) 61/39 63/37 NS
AF/Flutter (%) 87/13 82/18 NS
Underlying heart disease (%)*
Coronary artery disease 52 37 NS
Rheumatic valve disease 13 17 NS
Mitral valve disease 22 26 NS
Aortic valve disease 17 19 NS
Systemic hypertension 39 21 NS
Congenital heart disease 0 2 NS
Dilated cardiomyopathy 13 10 NS
'Lone' arrhythmia 9 9 NS
Arrhythmia History
Median duration, range (months) 20, 2-161 34, 1-348 .02
Number of: 
Previous electrical cardioversions 1.7 ± 1.0 2.0 ± 1.5 NS
Previous antiarrhythmic drugs 2.1 ± 0.7 1.9 ± 0.7 NS
Concomitant negative chronotropic 
medication during loading (%)
Digitalis 43 35 NS
Verapamil 35 16 .09
Both digitalis and verapamil 22 7 .06
Betablocker 9 3 NS
New York Heart Association
Class I (%) 22 24 NS
Class II (%) 57 51 NS
Class III-IV (%) 21 25 NS
Amiodarone level (mg/L) 2.0 ± 0.8 1.4 ± 0.7 .0003
DEA plasma level (mg/L) 1.4 ± 0.7 1.0 ± 0.5 .00001
* more than 1 disease entity per patient; DEA indicates desethylamiodarone
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Adverse  Events During the loading period,  patients (%) suffered from
minor gastrointestinal complaints, which disappeared spontaneously. No adverse
effects necessitating drug discontinuation occurred. There were no proarrhythmic
events, either in patients converting to sinus rhythm or in patiens remaining in .
The importance of amiodarone for long-term arrhythmia outcome after cardioversion
of  or flutter is well known.,- Amiodarone is also useful for pharmacologic
conversion of , with success rates ranging from % to as high as %-,-
depending upon patient characteristics and drug administration. The present study
showed that even in a highly selected group of patients refractory to antiarrhythmic
treatment, amiodarone was still able to restore sinus rhythm in % of the patients,
obliviating the need for electrical cardioversion. This is quite a remarkable number;
pharmacologic conversion by oral amiodarone was considered very unlikely to occur
in our patient group, because of a very long arrhythmia duration, large left atrial area
and proven refractoriness to previously instituted antiarrhythmic therapy.
The relation between plasma concentrations of amiodarone and desethylamio-
d i s c u s s i o n





Left atrial size, long axis view (mm) 47 ± 5 47 ± 7
Left atrial size, apical view (mm) 68 ± 6 71 ± 7
Left atrial area (mm2, calculated) 2502 ± 475 2620 ± 540
Right atrial size (mm) 60 ± 6 61 ± 7
LVEDD (mm) 52 ± 7 55 ± 8
LVESD (mm) 37 ± 9 39 ± 11
Fractional Shortening (%) 30 ± 9 29 ± 11
Electrocardiographic variables before amiodarone:
Heart rate (beats/min) 99 ± 20 100 ± 25
QRS (msec) 94 ± 12 96 ± 19
QT (msec) 386 ± 49 368 ± 45
QTc (msec) 456 ± 75 440 ± 64
Univariate analysis revealed no significant differences. n indicates number of patients; LVEDD, Left ventricular end-
diastolic diameter; LVESD, Left ventricular endsystolic diameter;  QTc, corrected QT-time.
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darone and clinical efficacy is not well established. Especially concerning supra-
ventricular arrhythmias, very limited data are available, Several investigators have
demonstrated only a weak or even absent concentration-effect relation.- Others
found a clear concentration related effect of amiodarone on -interval prolongation,
slowing of heart rate, and suppression of ventricular arrhythmias.- The present
study showed that for conversion of , plasma concentrations of desethylamiodarone
were more important than those of the parent compound. This is in agreement with
previous studies and is possibly related to a high myocardium/ plasma concentration
ratio in the case of desethylamiodarone. In contrast, reduction of the ventricular rate
during ongoing  was clearly correlated with plasme levels of amiodarone itself.
Because plasma levels of desethylamiodarone only increase gradually with prolonged
therapy, reaching approximately % of that of amiodarone in several months,,
conversion is expected to occur later, whereas effects on rate control will occur already
early after instituting therapy., Whether prolonged oral amiodarone loading is also
accompanied by an increase in the number of patients who undergo conversion
remains to be established.
A positive interaction between amiodarone and verapamil has not been reported
before. This could be explained by a pharmacokinetic drug interaction or by selection
bias. However, amiodarone plasma levels were not increased in patients using
verapamil and there were no differences in patient characteristics between patients
with and without concomitant treatment with verapamil. This preliminary finding
will have to be confirmed in a randomized placebo controlled study.
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Table 4 Multivariate analysis: parameters related to successful pharmacological conversion. 
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ratio CI
Desethylamiodarone level > 1.3 mg/L* 11.259 2.8-45.2 0.0006
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Left atrial area < 2689 mm2# 4.728 1.3-17.0 0.0176
*, third quartile; #, median; CI  indicates confidence interval.
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